Association between clinicopathological data and SOX2 gene status in NSCLC tumors. (PDF 101Â kb
Table S1. Primers for exon-specific sequencing of STK11 gene. Table S2. Native place of PJS patients...
Table S2. Pathogenic and likely pathogenic mutations identified in the studied cohort. Annotations a...
Relative enrichment of driver TFs domains for somatic mutations across approximately 7,000 tumors. (...
Table S1. The sequences of the primers used for HER2 and p53 analysis. (PDF 339 kb
Table S2. The sequences of the primers used for HER2 promoter analysis. (PDF 336 kb
The 207 tumor suppress genes (TSGs) with frequent copy number losses (CNLs). (XLSX 18 kb
Description of NSCLC cell lines used in this study. Information about histology, origin and disease ...
Table S1. Clinicopathological characteristics of 117 NSCLC patients. Table S2. The primers used in t...
Pathway analysis of RNA-Seq expression signature consisting of genes deregulated upon p53 knockdown....
Mini-signature of genes that interact with the p53 pathway and associated p values. (PDF 62 kb
Table S1. Correlation of SOX30 expression with clinicopathologic features in NSCLC patients (n = 537...
Figure S2. Clinical characteristics of the ESCC patients with TP53 mutations (G245C and R273H) in sm...
Table S1. Clinical characteristics of the enrolled 32 NSCLC patients. Table S2. List of target regio...
Sensitivity analysis (allele C vs. G) of TP53 rs1042522 and OL risk. (TIF 358 kb
Table S1. The primers and sequences for qPCR, siRNA, ChIP and RIP assays. (XLSX 12 kb
Table S1. Primers for exon-specific sequencing of STK11 gene. Table S2. Native place of PJS patients...
Table S2. Pathogenic and likely pathogenic mutations identified in the studied cohort. Annotations a...
Relative enrichment of driver TFs domains for somatic mutations across approximately 7,000 tumors. (...
Table S1. The sequences of the primers used for HER2 and p53 analysis. (PDF 339 kb
Table S2. The sequences of the primers used for HER2 promoter analysis. (PDF 336 kb
The 207 tumor suppress genes (TSGs) with frequent copy number losses (CNLs). (XLSX 18 kb
Description of NSCLC cell lines used in this study. Information about histology, origin and disease ...
Table S1. Clinicopathological characteristics of 117 NSCLC patients. Table S2. The primers used in t...
Pathway analysis of RNA-Seq expression signature consisting of genes deregulated upon p53 knockdown....
Mini-signature of genes that interact with the p53 pathway and associated p values. (PDF 62 kb
Table S1. Correlation of SOX30 expression with clinicopathologic features in NSCLC patients (n = 537...
Figure S2. Clinical characteristics of the ESCC patients with TP53 mutations (G245C and R273H) in sm...
Table S1. Clinical characteristics of the enrolled 32 NSCLC patients. Table S2. List of target regio...
Sensitivity analysis (allele C vs. G) of TP53 rs1042522 and OL risk. (TIF 358 kb
Table S1. The primers and sequences for qPCR, siRNA, ChIP and RIP assays. (XLSX 12 kb
Table S1. Primers for exon-specific sequencing of STK11 gene. Table S2. Native place of PJS patients...
Table S2. Pathogenic and likely pathogenic mutations identified in the studied cohort. Annotations a...
Relative enrichment of driver TFs domains for somatic mutations across approximately 7,000 tumors. (...
DOI
Add to ORKG